ArticleClinical rheumatology2026
Association between biological aging and clinical mortality among patients with rheumatoid arthritis.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBiological aging constitutes a well-recognized risk factor for age-associated diseases; nevertheless, its specific impact on individuals with rheumatoid arthritis (RA) has not been comprehensively elucidated. This study aimed to investigate the relationships between biological aging and clinical outcomes, including reductions in life expectancy, among patients with RA.
methodsWe analyzed data from 45,119 participants of the National Health and Nutrition Examination Survey (NHANES). Biological aging was quantified using the recently validated Gompertz Law-Based Biological Age (GOLD BioAge) metric. Additionally, accelerated biological aging was determined by calculating the discrepancy between biological age and chronological age. A simplified version of the GOLD BioAge, referred to as Light BioAge, was also examined. Logistic regression models were applied to assess the cross-sectional association between biological aging and RA. Longitudinal relationships between biological aging and the incidence of cardiovascular disease (CVD), heart disease, and malignancies were evaluated using Cox proportional hazards models. Furthermore, threshold effect analyses were conducted to explore potential non-linear associations.
resultsPatients with RA exhibited pronounced accelerated biological aging, which was identified as a significant risk factor for RA based on both GOLD BioAge and Light BioAge measures. GOLD BioAge demonstrated a significant association with increased all-cause mortality and cancer risk among RA patients, with threshold effect analysis revealing a non-linear relationship (p < 0.05). Moreover, RA patients exhibiting substantial acceleration in GOLD BioAge showed a proportionally increased risk of mortality attributable to CVD, heart disease, and malignancies, characterized by a linear association (p > 0.05).
conclusionsBiological aging is closely associated with a heightened risk of all-cause mortality and decreased life expectancy in individuals diagnosed with RA. Therefore, therapeutic interventions targeting the fundamental biological mechanisms of aging may represent a promising avenue for mitigating morbidity in this vulnerable population. Key Points • Accelerated biological aging was prominently observed in patients with RA and identified as a substantial risk factor for the disease, as assessed by both the GOLD BioAge and Light BioAge metrics. • The GOLD BioAge measure exhibited a significant association with increased all-cause mortality and cancer risk in RA patients, characterized by a non-linear relationship. • Furthermore, RA patients exhibiting pronounced acceleration in GOLD BioAge demonstrated a proportionally elevated risk of mortality attributable to cardiovascular disease, heart disease, and malignancies, following a linear association.
Indexed as
Identifiers
41986601What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.